April 24–30 is Canadian Infertility Awareness Week. It wasn’t that long ago that people living with HIV faced…

To mark International Women’s Day, we sat down with the CTN 335 investigators to learn about how their…
The drug works against CMV, a common virus that may be a main cause of inflammation and health…
Ahead of World Cancer Day, we spoke with Dr. Troy Grennan about anal cancer screening among gbMSM living…

A new national study, called HIVCOV (CTN 328), will assess COVID-19 vaccine immune responses and effectiveness among people…
March 31 marks the International Transgender Day of Visibility, an annual event dedicated to celebrating transgender (trans) people…
As a physical therapist, Dr. Adria Quigley has always been fascinated by how the brain works. Learn about…
Dr. Elizabeth King is an infectious disease specialist who joined the CTN as a Postdoctoral Fellow in July…
The WHO-funded study shows that dolutegravir is the optimal choice for first-line treatment of HIV
Our Resource Library is a place to share documents, videos, and training resources about HIV and STBBI research and related topics.
There are no results message
The CTN+ supports clinical trials, implementation science projects, and non-interventional research of the highest scientific and ethical standards.
REducing SysTemic inflammation for people on AntiRetroviral Therapy
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Project ReportNeedles.ca: A rapid assessment and response system to map needle prevalence and implement harm reduction interventions in Regina, Saskatchewan
A randomized prospective open-label study of switching to raltegravir based antiretroviral therapy (ART) compared to maintaining ritonavir boosted protease inhibitor-based ART on liver fibrosis progression in HIV-HCV co-infected individuals
Our researchers and trainees have produced hundreds of peer-reviewed publications in a wide range of HIV- and STBBI-related areas.
Related Study: